The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.40
Bid: 4.12
Ask: 4.70
Change: 0.94 (27.09%)
Spread: 0.58 (14.078%)
Open: 3.64
High: 4.80
Low: 3.64
Prev. Close: 3.47
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Approval for Sale of Harpin aß Granted in Poland

1 Aug 2023 07:00

RNS Number : 8199H
Plant Health Care PLC
01 August 2023
 

RNS

01 August 2023

 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Approval for Sale of Harpin αβ Granted in Poland

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce that Harpin αβ, the Company's core, high-value fertilizer product with biostimulant properties, has successfully achieved Mutual Recognition in Poland. This is a major milestone for the Company, and permits immediate sales of Harpin αβ in Poland. Poland is the sixth largest agricultural producer in the EU, and the second largest potato producer behind Germany, growing around 322,000 hectares.

 

Following the initial regulatory approval in France in October 2022, Plant Health Care has pursued Mutual Recognition to expand the use of Harpin αβ across Europe and Poland is the first EU country to grant this status for Harpin αβ.. Europe is the world's largest market for sustainable agriculture with annual sales of over $2 billion.

 

Harpin αβ is a recombinant protein that acts as a powerful biostimulant, improving the yield and quality of crops. Plant Health Care is launching Harpin αβ for use in European potato production, followed by fruit and vegetable crops. Potato field trials are currently underway in Germany, France, Belgium and the Netherlands to demonstrate the value of Harpin αβ. The Company sells Harpin αβ through specialist distributors around the world. Visits to the field trials with interested distributors to observe the results of Harpin αβ on treated potato plants are planned for mid-August.

 

Angel Marin, Director EMEAA for Plant Health Care, said: ‟Expanding the use of our core product, Harpin αβ, in Europe's biggest agricultural markets has been a long-term goal of mine. The granting of Mutual Recognition by Poland brings us one-step closer and the Company expects to select our distribution partner for France, Poland and other EU countries by the end of the year. Harpin αβ is an environmentally friendly, and proven protein technology which improves plant growth and development resulting in higher quality, yields and long-term storage stability, which are vital as the world becomes more concerned about food security."

 

For further information, please contact: 

 Plant Health Care plc  Jeff Tweedy, CEO

 

+1 919 926 1600

 Cenkos Securities plc - Nomad & Broker  Neil McDonald / Pete Lynch

 

+44 (0) 131 220 9771

 SEC Newgate (Financial Communications)  Robin Tozer / Harry Handyside / George Esmond

+44 (0)7540 106 366 phc@secnewgate.co.uk

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile. 

 

Find out more at www.planthealthcare.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFLLXXDLZBBK
Date   Source Headline
18th Aug 20214:41 pmRNSSecond Price Monitoring Extn
18th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20211:27 pmRNSHolding(s) in Company
3rd Aug 20217:00 amRNSAdmission to the U.S. OTCQB Venture Market
27th Jul 20217:00 amRNSNew Distribution Agreement with Agrii UK
26th Jul 20217:00 amRNS2021 Half-Year Trading Statement
23rd Jul 20217:00 amRNSGrant of Options
22nd Jul 20217:00 amRNSInvestor Presentation
12th Jul 20214:40 pmRNSSecond Price Monitoring Extn
12th Jul 20214:35 pmRNSPrice Monitoring Extension
29th Jun 20214:41 pmRNSSecond Price Monitoring Extn
29th Jun 20214:35 pmRNSPrice Monitoring Extension
14th Jun 20212:33 pmRNSResult of AGM
14th Jun 20217:00 amRNSGreen Economy Mark awarded
9th Jun 20214:41 pmRNSSecond Price Monitoring Extn
9th Jun 20214:35 pmRNSPrice Monitoring Extension
20th May 20217:00 amRNSInvestor Presentation
7th May 20213:50 pmRNSAnnual Report & Accounts and AGM Notice Published
30th Apr 20215:40 pmRNSHolding(s) in Company
23rd Apr 20217:00 amRNSResults for the year ended 31 December 2020
21st Apr 202111:58 amRNSHolding(s) in Company
8th Apr 20213:30 pmRNSHolding(s) in Company
1st Apr 20217:00 amRNSTotal Voting Rights
22nd Mar 20217:00 amRNSInvestor Presentation
18th Mar 20211:57 pmRNSResults of Placing and Subscription
18th Mar 20217:00 amRNSProposed Placing and Subscription
1st Mar 20217:00 amRNSSaori Trial Update
3rd Feb 20214:41 pmRNSSecond Price Monitoring Extn
3rd Feb 20214:36 pmRNSPrice Monitoring Extension
27th Jan 20214:41 pmRNSSecond Price Monitoring Extn
27th Jan 20214:36 pmRNSPrice Monitoring Extension
25th Jan 20217:00 amRNSTrading Statement
11th Jan 20217:00 amRNSNotice of Trading Statement/Investor Presentation
5th Jan 20213:37 pmRNSBrazil approves PHC279 to Control Soybean Rust
11th Dec 20207:00 amRNSInvestor Presentation
9th Nov 20207:00 amRNSPlant Health Care and Wilbur-Ellis sign Agreement
7th Oct 20207:00 amRNSGrant of Options
6th Oct 20207:00 amRNSNew US PREtec Patents Issued
2nd Oct 20205:48 pmRNSSignificant Shareholder
25th Sep 20207:00 amRNSInvestor Presentation
23rd Sep 20207:00 amRNSInvestor Presentation
15th Sep 20207:00 amRNSInterim Report 30 June 2020
29th Jul 20207:00 amRNSTrading Statement
26th Jun 20204:41 pmRNSSecond Price Monitoring Extn
26th Jun 20204:36 pmRNSPrice Monitoring Extension
25th Jun 20207:00 amRNSGrant of Options
18th Jun 20204:41 pmRNSSecond Price Monitoring Extn
18th Jun 20204:36 pmRNSPrice Monitoring Extension
16th Jun 20207:00 amRNSPHC398 Approved by US EPA: PHC279 submitted to EPA
9th Jun 20207:00 amRNSGrant of options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.